In 2003 Medicare extended coverage of ventricular assist devices (VAD) as destination (permanent) therapy for end-stage heart failure in the USA. Hernandez et al. performed an analysis to determine the short- and long-term clinical outcomes of patients receiving VAD therapy, as well as the costs involved, since this change. […]